Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial.

Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent... Treatment of latent tuberculosis infection with isoniazid for 9 months is complicated by poor patient adherence and the need for close follow-up of side effects, especially hepatotoxicity. Shorter and safer regimens are needed. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Annals of internal medicine Pubmed

Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial.

Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial.


Abstract

Treatment of latent tuberculosis infection with isoniazid for 9 months is complicated by poor patient adherence and the need for close follow-up of side effects, especially hepatotoxicity. Shorter and safer regimens are needed.

Loading next page...
 
/lp/pubmed/adverse-events-with-4-months-of-rifampin-therapy-or-9-months-of-DvBouROZHH

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

ISSN
0003-4819
eISSN
1539-3704
DOI
10.7326/0003-4819-149-10-200811180-00003
pmid
19017587

Abstract

Treatment of latent tuberculosis infection with isoniazid for 9 months is complicated by poor patient adherence and the need for close follow-up of side effects, especially hepatotoxicity. Shorter and safer regimens are needed.

Journal

Annals of internal medicinePubmed

Published: Dec 3, 2008

There are no references for this article.